ClinicalTrials.gg
RecruitingNCT07095998Updated Apr 22, 2026

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

An interventional study of Threshold Tracking Nerve Conduction Studies in Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy and Neurotoxicity Syndromes, sponsored by Ka-Wai Ho. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Ka-Wai Ho · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.

Planned enrollment
50th of 157
60 · median 43
Started
2026
with 12 others
No phase
91 of 191
19 open now
Primary completion
2027-08
later than 23 of 46 live
Registered
178th of 191
by date

Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 50th largest by planned enrollment of the 157 interventional ones that give a count, is one of 13 that started in 2026, is one of 91 with no phase, reaches primary completion later than 23 of the 46 other live ones, and was the 178th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Peripheral Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.

Read the detailed description

This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.

Peripheral neuropathy is a sensory disorder where patients feel a burning, tingling, or pins-and-needles sensation in the hands and feet that can lead to oversensitivity or numbness.

The U.S. Food and Drug Administration (FDA) has not approved DS5 0 Isolated Bipolar Constant Current Stimulator as a diagnostic tool for Peripheral Neuropathy.

The research study procedures include screening for eligibility, in-clinic visits, blood tests, questionnaires, and standard neurological exams called nerve conduction studies and Threshold tracking nerve conduction studies.

Participants will be placed into one of the following groups:

  • Cohort A: Participants without previous treatment with cisplatin and are about to start treatment with Cisplatin.
  • Cohort B: Participants with previous treatment with cisplatin in the past 3 months (and no longer being treated with cisplatin) and are currently experiencing cisplatin- induced peripheral neuropathy.

It is expected that about 60 people will take part in this research study.

03

Conditions studied

  • Peripheral Neuropathy Due to Chemotherapy
  • Peripheral Neuropathy
  • Neurotoxicity Syndromes
  • Neuropathy

Keywords

  • Peripheral Neuropathy Due to Chemotherapy
  • Peripheral Neuropathy
  • Neurotoxicity Syndromes
  • Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Cohort A:

  • Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.
  • Participants must have adequate hematologic parameters to allow chemotherapy.

Exclusion Criteria Cohort A:

  • Pre-existing peripheral neuropathy;
  • Family history of a genetic/familial neuropathy;
  • Any for treatment with cisplatin as determined by their primary oncologist;
  • Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
  • Patients with cardiac or spinal stimulating devices;
  • Women who are pregnant or breastfeeding;
  • Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
  • Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
  • Patients not considered to be able to comply with the protocol.

Inclusion Criteria Cohort B:

  • Adults age ≥ 18 with a diagnosis of cis-PN.
  • The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy.

Exclusion Criteria Cohort B:

  • Pre-existing peripheral neuropathy;
  • Family history of a genetic/familiar neuropathy;
  • History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
  • Patients with cardiac or spinal stimulating devices;
  • Women who are pregnant or breastfeeding;
  • Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
  • Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
  • Patients not considered to be able to comply with the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort A: Participants Without Cisplatin-Induced Peripheral Neuropathy

    30 participants with no baseline neuropathy symptoms will be enrolled prior to starting cisplatin-based chemotherapy and will complete the following: * Baseline visit with neurological exams and conduction studies * Standard of care chemotherapy infusion (duration may vary depending on the chemotherapy regimen received) * Post-Infusion study visits via phone call (number of visits may vary depending on the chemotherapy regimen received) * In-clinic visit with neurological exams and conduction studies if participants develop cis-PN symptoms --If participants do not develop cis-PN symptoms, participants will be reevaluated 1 month post end of cisplatin treatment * 7-day end of treatment visit via phone call * 1-month post-treatment visit with neurological exams and conduction studies

    Diagnostic Test: Threshold Tracking Nerve Conduction Studies

  • Experimental
    Cohort B: Participants with Cisplatin-Induced Peripheral Neuropathy

    30 participants with cis-PN symptoms will be enrolled and will complete the following: -One-time visit with neurological exams and conduction studies

    Diagnostic Test: Threshold Tracking Nerve Conduction Studies

Interventions

  • Diagnostic testThreshold Tracking Nerve Conduction Studies

    Measurement of nerve excitability parameters, including response to sub-threshold pre-pulses and other stimuli. The DS5 0 Isolated Bipolar Constant Current Stimulator is a non-invasive, non-therapeutic device that provides controlled electrical stimuli for detailed function assessment of the superficial radial, superficial peroneal, ulnar, and sural nerves.

    Also known as: TTNC, TTNCS

06

What researchers measure

Primary outcomes

  1. Presence of change in Nerve Excitability in comparison to baseline nerve excitability.

    Nerve excitability will be assessed via Threshold Tracking Nerve Conduction Study (TTNCS). Excitability parameters collected will include refractoriness, superexcitability, extent of threshold change in threshold electrotonus (hyperpolarizing 90-100ms). A composite excitability score is calculated to assess overall change in excitability parameters, all of which are weighted equally (Park, S.B., Lin, C.S.Y., Kiernan, M.C. Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity.J. Vis. Exp. (62), e3439, doi:10.3791/3439 (2012).

    Time frame: For Arm A, the time frame is at baseline and within 24 weeks of cisplatin initiation. For Arm B, the time frame is during the TTNCS procedure.

Secondary outcomes

  1. Number of participants who develop neuropathy symptoms as assessed by CTCAE v. 5.0.

    The Wilcoxon signed rank test (two tailed) will be used to compared measurements at these time points.

    Time frame: For Arm A, peripheral neuropathy symptoms will be assessed at baseline and the time of the development of Cis-PN symptoms over the course of 24 weeks. For Arm B, symptoms will be assessed immediately before the TTNCS procedure.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 122 non-industry interventional studies with no phase under Peripheral Nervous System Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 132 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jul 31, 2025
StartActual
Jan 31, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095998
Lead sponsor
Ka-Wai Ho
Responsible party
Ka-Wai Ho (Sponsor-Investigator, Beth Israel Deaconess Medical Center) — Sponsor-investigator
First posted
Jul 31, 2025
Start date
Jan 31, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Ka-Wai Ho, MD
Contact
Kho5@bidmc.harvard.edu
617-667-1665
Ka-Wai Ho, MD
principal investigator · Beth Israel Deaconess Medical Center
Tamar Berger, MD PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion